AR081197A1 - Lactamas sustituidas con piperidinil o como moduladores de gpr 119 - Google Patents
Lactamas sustituidas con piperidinil o como moduladores de gpr 119Info
- Publication number
- AR081197A1 AR081197A1 ARP110101683A ARP110101683A AR081197A1 AR 081197 A1 AR081197 A1 AR 081197A1 AR P110101683 A ARP110101683 A AR P110101683A AR P110101683 A ARP110101683 A AR P110101683A AR 081197 A1 AR081197 A1 AR 081197A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- halogen
- methyl
- Prior art date
Links
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- -1 (cyclopropylmethyl) sulfonyl Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Son moduladores de GPR119 y son útiles en el tratamiento o la prevención de enfermedades tales como, en forma no taxativa, diabetes tipo 2, complicaciones diabéticas, síntomas de la diabetes, síndrome metabólico, obesidad, dislipidemia y condiciones relacionadas. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula general (1 ) o una sal farmacéuticamente aceptable o un solvato de él, en donde L es O o NRx; Rx es H o alquilo C1-3; X1 es N o CR1 y X2 es N o CR2, en donde solamente uno de X1 y X2 puede ser N; R1, R2, R3 y R4 se seleccionan independientemente de H, halógeno, CF3, alquilo C1-6 y alcoxi C1-6; R5 es alquilo C1-3sulfonilo, cicloalquilo C3-6 sulfonilo, (ciclopropilmetil)sulfonilo, fenilsulfonilo, CN, Br, CF3, triazolilo, alcoxi C1-4carbonilo, RxRyNHC(=O)-, oxadiazolilo opcionalmente sustituido con alquilo C1-3, y tetrazolilo opcionalmente sustituido con alquilo C1-3; o cuando X1 es CR1 y X2 es CR2, entonces R4 y R5 opcionalmente junto con los átomos a los cuales están unidos forman un anillo heterocíclico saturado de 5-6 miembros que tiene 1-2 heteroátomos del anillo seleccionados independientemente de O y S y opcionalmente sustituidos con un grupo oxo, en donde el S cuando está presente está opcionalmente oxidado; Rx y Ry son independientemente alquilo C1-4) opcionalmente sustituido con OH, o Rx y Ry junto con el átomo al cual están unidos forman un anillo azacíclico saturado de 5-6 miembros opcionalmente sustituidos con OH; R6 es H, OH o metilo; R6a es H o metilo; R7 es un grupo que tiene la estructura de fórmulas (2); A1 es N o CRa; A2 es N o CRb; A3 es N o CRc; A4 es N o CRd, en donde por lo menos uno de A1, A2, A3 y A4 es N, y no más de dos de A1, A2, A3 y A4 pueden ser N; Ra, Rb, Rc y Rd son independientemente H, CF3, halógeno, alquilo C1-4 o CN; R8 se selecciona de hidrógeno, halógeno CF3, CN, alquilo C1-10, hidroxialquilo C1-6, alcoxi C1-6, alquilo C1-6sulfanilo, fenilo, piridilo, pirimidilo, pirazolilo, y dialquilo C1-3carbamilo, en donde cada uno de dichos fenilo, piridilo, pirimidilo, y pirazolilo se sustituye opcionalmente con uno o más sustituyentes seleccionados independientemente de alquilo C1-4, alcoxi C1-4 y CF3; R9 y R9a son independientemente hidrógeno o metilo; y n es 1, 2 o 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34546110P | 2010-05-17 | 2010-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081197A1 true AR081197A1 (es) | 2012-07-04 |
Family
ID=44584599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101683A AR081197A1 (es) | 2010-05-17 | 2011-05-17 | Lactamas sustituidas con piperidinil o como moduladores de gpr 119 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8754226B2 (es) |
| EP (1) | EP2571864A1 (es) |
| JP (1) | JP2013530947A (es) |
| KR (1) | KR20130113948A (es) |
| CN (1) | CN103080101A (es) |
| AR (1) | AR081197A1 (es) |
| AU (1) | AU2011256455A1 (es) |
| BR (1) | BR112012029395A2 (es) |
| CA (1) | CA2799779A1 (es) |
| CL (1) | CL2012003211A1 (es) |
| CO (1) | CO6670520A2 (es) |
| CR (1) | CR20120642A (es) |
| IL (1) | IL223092A0 (es) |
| MX (1) | MX2012013465A (es) |
| RU (1) | RU2012154308A (es) |
| SG (1) | SG185615A1 (es) |
| TW (1) | TW201141849A (es) |
| UY (1) | UY33392A (es) |
| WO (1) | WO2011146335A1 (es) |
| ZA (1) | ZA201209605B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013465A (es) | 2010-05-17 | 2013-12-02 | Array Biopharma Inc | Lactamas sustituidas con piperidinilo como moduladores de gpr119. |
| WO2014011926A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| EP2892897A1 (en) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| WO2014195276A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| RU2016143092A (ru) | 2014-04-04 | 2018-05-08 | Санофи | Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| TW201623286A (zh) | 2014-04-04 | 2016-07-01 | 賽諾菲公司 | 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物 |
| US20170342304A1 (en) * | 2015-01-19 | 2017-11-30 | Fujimi Incorporated | Polishing composition |
| CN110316737A (zh) | 2015-01-19 | 2019-10-11 | 福吉米株式会社 | 改性胶体二氧化硅及其制造方法、以及使用其的研磨剂 |
| BR112018012338A2 (pt) | 2015-12-17 | 2018-12-04 | Syngenta Participations Ag | derivados de oxadiazol microbiocidas |
| WO2018153849A1 (en) | 2017-02-21 | 2018-08-30 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| BR112022023359A2 (pt) | 2020-05-19 | 2023-04-18 | Kallyope Inc | Ativadores de ampk |
| EP4168392A1 (en) | 2020-06-22 | 2023-04-26 | F. Hoffmann-La Roche AG | Sulfone derivatives |
| EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| WO2024126650A1 (en) | 2022-12-15 | 2024-06-20 | Syngenta Crop Protection Ag | Novel bicyclic-carboxamide compounds useful as pesticides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| CN101090885A (zh) | 2004-02-23 | 2007-12-19 | 塔夫茨大学信托人 | 作为构象限定的肽模拟物抑制剂的内酰胺类化合物 |
| TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| WO2005121121A2 (en) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006057921A2 (en) * | 2004-11-22 | 2006-06-01 | Merck & Co., Inc. | Piperidinyl piperidine tachykinin receptor antagonists |
| WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| WO2006104280A1 (ja) * | 2005-03-31 | 2006-10-05 | Takeda Pharmaceutical Company Limited | 糖尿病の予防・治療剤 |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| CA2613235A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| NZ564758A (en) | 2005-06-30 | 2011-03-31 | Prosidion Ltd | G-protein coupled receptor agonists |
| US20080025795A1 (en) * | 2006-07-28 | 2008-01-31 | Cliff Purnell | Methods, apparatus and system for drain tiles |
| WO2008025799A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
| CA2672307A1 (en) | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
| BRPI0814294A2 (pt) | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
| ES2387865T3 (es) | 2008-07-10 | 2012-10-03 | Prosidion Ltd | Agonistas de GPCR de piperidina |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| JP5699149B2 (ja) * | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬 |
| MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
| MX2012013465A (es) | 2010-05-17 | 2013-12-02 | Array Biopharma Inc | Lactamas sustituidas con piperidinilo como moduladores de gpr119. |
| SG188985A1 (en) | 2010-09-17 | 2013-05-31 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators |
| WO2013066869A1 (en) | 2011-11-03 | 2013-05-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
| US20140309226A1 (en) | 2011-11-16 | 2014-10-16 | Array Biopharma Inc. | Piperidinyl-substituted cyclic ureas as gpr119 modulators |
-
2011
- 2011-05-13 MX MX2012013465A patent/MX2012013465A/es not_active Application Discontinuation
- 2011-05-13 RU RU2012154308/04A patent/RU2012154308A/ru not_active Application Discontinuation
- 2011-05-13 EP EP11754769A patent/EP2571864A1/en not_active Withdrawn
- 2011-05-13 BR BR112012029395A patent/BR112012029395A2/pt not_active IP Right Cessation
- 2011-05-13 KR KR1020127032867A patent/KR20130113948A/ko not_active Application Discontinuation
- 2011-05-13 WO PCT/US2011/036443 patent/WO2011146335A1/en active Application Filing
- 2011-05-13 JP JP2013511238A patent/JP2013530947A/ja not_active Withdrawn
- 2011-05-13 CN CN2011800291586A patent/CN103080101A/zh active Pending
- 2011-05-13 SG SG2012084471A patent/SG185615A1/en unknown
- 2011-05-13 AU AU2011256455A patent/AU2011256455A1/en not_active Abandoned
- 2011-05-13 US US13/698,257 patent/US8754226B2/en not_active Expired - Fee Related
- 2011-05-13 CA CA2799779A patent/CA2799779A1/en not_active Abandoned
- 2011-05-17 UY UY0001033392A patent/UY33392A/es not_active Application Discontinuation
- 2011-05-17 TW TW100117276A patent/TW201141849A/zh unknown
- 2011-05-17 AR ARP110101683A patent/AR081197A1/es unknown
-
2012
- 2012-11-16 CL CL2012003211A patent/CL2012003211A1/es unknown
- 2012-11-18 IL IL223092A patent/IL223092A0/en unknown
- 2012-12-17 CO CO12228271A patent/CO6670520A2/es not_active Application Discontinuation
- 2012-12-17 CR CR20120642A patent/CR20120642A/es unknown
- 2012-12-18 ZA ZA2012/09605A patent/ZA201209605B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8754226B2 (en) | 2014-06-17 |
| AU2011256455A1 (en) | 2013-01-10 |
| CR20120642A (es) | 2013-03-11 |
| CN103080101A (zh) | 2013-05-01 |
| BR112012029395A2 (pt) | 2016-07-26 |
| IL223092A0 (en) | 2013-02-03 |
| KR20130113948A (ko) | 2013-10-16 |
| MX2012013465A (es) | 2013-12-02 |
| JP2013530947A (ja) | 2013-08-01 |
| EP2571864A1 (en) | 2013-03-27 |
| CO6670520A2 (es) | 2013-05-15 |
| WO2011146335A1 (en) | 2011-11-24 |
| CA2799779A1 (en) | 2011-11-24 |
| CL2012003211A1 (es) | 2013-04-26 |
| TW201141849A (en) | 2011-12-01 |
| SG185615A1 (en) | 2012-12-28 |
| UY33392A (es) | 2012-11-30 |
| ZA201209605B (en) | 2014-05-28 |
| RU2012154308A (ru) | 2014-06-27 |
| US20130158009A1 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081197A1 (es) | Lactamas sustituidas con piperidinil o como moduladores de gpr 119 | |
| AR083003A1 (es) | Lactamas sustituidas por piperidinilo como moduladores de gpr119 | |
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| AR082446A1 (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
| PE20141211A1 (es) | Moduladores receptores de hormonas nucleares | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| IN2014MN01897A (es) | ||
| PE20160839A1 (es) | Derivados de 4-azaindol | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| ECSP13012980A (es) | Derivados de fenil- o piridinil-etinilo | |
| AR080151A1 (es) | Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia | |
| AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
| DOP2014000287A (es) | Compuestos de fenoxietil piperidina | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
| JP2010155827A5 (es) | ||
| BR112015005186A2 (pt) | 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
| AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |